www.fdanews.com/articles/74768-millennium-pharmaceuticals-loss-narrows
MILLENNIUM PHARMACEUTICALS LOSS NARROWS
July 28, 2005
Biotechnology company Millennium Pharmaceuticals Inc. (MLNM.O: Quote, Profile, Research) on Thursday said its quarterly loss narrowed on lower costs and higher sales of its bone cancer drug Velcade. The second-quarter net loss was $44.1 million, or 14 cents a share, compared with a net loss of $53.9 million, or 18 cents a share, a year ago. Excluding one-time items, Millennium lost 11 cents a share in the latest quarter. Analysts on average had expected Cambridge, Massachusetts-based Millennium to post a loss of 10 cents a share, according to Reuters Estimates.